OUR CONTRIBUTION AGAINST DISEASES NO. 1

Here you will find important information on the progress of the BELACT project.

NEW ENZYM
– with promising effect in preclinical study

Baar, 28.12.2023 – In a preclinical study, the novel, genetically engineered enzyme preparation BELACT was able to significantly reduce the severity of advanced atherosclerosis in laboratory animals. The conditions of severe lipometabolic disorders in humans were simulated using an established animal model.

Read more here: Preclinical study – Summary of results.

PHARMACT HOLDING AG
– ACHIEVES POSITIVE ADVISORY RESULT FOR BELACT

20.04.2024 – Pharmact Holding AG is pleased to announce an important development update on our BELACT hyaluronidase candidate: During a scientific consultation with the Federal Institute for Drugs and Medical Devices (BfArM), Bonn, we received very positive feedback and guidance.

Read more here: Development update.

SUMMARY
– Familial hypercholesterolaemia

04.10.2024 – Familial hypercholesterolaemia is one of the main causes of accelerated atherosclerosis/arteriosclerosis, which in its homozygous form can lead to heart attacks in children as young as 5 years old and gives affected patients a maximum life expectancy of around 25 years despite intensive therapy such as statins, PCSK-9 inhibitors and lipidapheresis.

Read more here: Familial hypercholesterolaemia.